Table 4b: Costs of adverse effects: Results after TTR increase to 78%.
| NOAC | Cost per patient (NOAC) in € | Cost per patient (VKA) in € | Difference to VKA per patient in € | Adverse events costs per patient (NOAC) in € | Adverse event costs per patient (VKA) in € | Difference of adverse events costs to VKA per patient in € |
|---|---|---|---|---|---|---|
| Rivaroxaban | 1510.93 | 748.29 | - 762.64 | 202.94 | 150.32 | - 52.62 |
| Dabigatran | 1480.81 | 768.64 | - 712.17 | 169.64 | 170.67 | + 1.03 |
| Apixaban | 1583.54 | 837.78 | - 745.76 | 216.40 | 239.81 | + 23.41 |
| Edoxaban | 1382.88 | 779.51 | - 603.38 | 181.0 | 181.54 | + 0.53 |